CKI primarily addresses liver cancer through the modulation of diverse pathways, such as neuroactive ligand–receptor interactions, the cAMP signaling pathway, various cancer-related pathways, and serotonergic synapse activity. This evidence concerns the gene CHKA and liver cancer.